United States Patent 3,681,357: Scope, Claims, and US Patent Landscape
United States Patent 3,681,357 is the US grant for a topical treatment using a compound described as “miconazole” (and related azole antifungal chemistry) for fungal infections of skin. The patent’s enforceable scope centers on (1) the specific active antifungal agent and its defined formulation and (2) the application to topical infection conditions rather than systemic dosing. The practical landscape in the US is shaped by later azole-family filings and by independent patent families covering formulation vehicles, concentration ranges, and dosing regimens for topical antifungals.
What is US Patent 3,681,357 and what does it protect?
US Patent 3,681,357 is directed to a topical antifungal pharmaceutical composition and its use for treating fungal infections. The claim set reflects a classic early-azole patent structure: it ties protection to the active antifungal compound and to topical pharmaceutical preparations intended for treating mycotic skin conditions.
Core claim themes (scope drivers):
- Active ingredient is an azole antifungal (miconazole): claim language anchors the protected invention to the specific compound identity.
- Topical pharmaceutical preparation: claims require a formulation suitable for topical administration (vehicle and composition structure).
- Treatment of fungal infections: method claims and use claims connect the formulation to therapeutic effect for skin mycoses.
Practical scope boundary:
- Protection is composition and topical-use centered rather than broad “any antifungal” coverage.
- The enforceable perimeter depends heavily on whether later products use the same active compound (or close chemical variants that fall within claim language) and whether their formulation structure tracks claim requirements.
Source: US Patent 3,681,357 (full text and claim set). [1]
What do the claims cover, and what are the enforceable elements?
What are the main claim categories?
US 3,681,357’s claim set is organized around two main protection mechanisms:
-
Pharmaceutical composition claims
- Define a topical formulation containing miconazole.
- Typically specify ingredient relationships and allowable formulation components (excipients/vehicles) that make the preparation topical and stable for administration. [1]
-
Method/use claims
- Define treatment of fungal infections by applying the topical composition to an affected area.
- The claims focus on topical treatment rather than oral or parenteral delivery. [1]
What are the key claim elements that determine infringement?
For most topical antifungal patents of this era, infringement turns on whether a product satisfies all of the required elements in claim language. For US 3,681,357, the high-sensitivity elements are:
- The active ingredient must match the claim definition (miconazole as described). [1]
- The dosage form must be topical (a formulation designed for skin application). [1]
- The therapeutic use must be consistent with treatment of fungal infections as claimed. [1]
- The formulation structure must stay within claimed formulation constraints (if the independent claims include vehicle/excipient limitations). [1]
How broad is the claim scope in practice?
Breadth by active ingredient
If a later topical antifungal product uses a different azole (e.g., clotrimazole, ketoconazole, econazole, etc.) rather than miconazole, the product generally falls outside the claim anchor unless the claims include coverage for azole compounds broadly. In US 3,681,357, the protection is centered on miconazole, which makes active-ingredient identity the first gating factor. [1]
Breadth by formulation
Even with the same active, breadth depends on formulation limitations:
- If independent composition claims require specific vehicle types or composition relationships, a different vehicle can avoid infringement.
- If dependent claims cover narrower ranges or specific formulation embodiments, those ranges become key for design-around strategies. [1]
Breadth by treatment method
If claims specify topical application to treat specified fungal infections, then a product labeled for different indications (or used exclusively off-label) may reduce risk against method/use claims. The patent ties treatment to fungal skin conditions, not systemically treated infections. [1]
What is the patent landscape around this filing (US focus)?
How does the landscape cluster for topical azole antifungals?
In the US market, the azole antifungal landscape clusters into four overlapping patent buckets:
-
Early active-ingredient enablement and first therapeutic formulations
- Claims anchored on the first identified azole compound(s) and their topical use.
- US 3,681,357 sits in this cluster by virtue of its topical antifungal composition and use focus. [1]
-
Formulation vehicle and delivery-technology improvements
- Later patents cover gels, creams, solutions, powders, sprays, penetration enhancers, and stability improvements.
- These often produce around early composition claims while keeping the same active.
-
Concentration range and dosing regimen refinements
- Follow-on filings tune concentrations, frequency of application, and duration.
-
Polymorphs/solid forms and manufacturing-process patents
- Changes to crystalline form, particle size, or process steps can support separate patent estates even when the active ingredient remains unchanged.
Where do later patents typically compete against 3,681,357?
Competitors typically intersect with US 3,681,357 in the following ways:
- Same active (miconazole) + different formulation vehicle: risk depends on how strictly composition claims specify excipients/vehicle structure.
- Same topical delivery but different concentration or dosing regimen: may be riskier if the claims cover the regimen explicitly, but often shifts to dependent claim territory.
- Different azole actives: tends to be outside scope if claims require miconazole identity.
What does the landscape imply for freedom-to-operate (FTO) around topical miconazole?
If you formulate miconazole for topical use
FTO risk concentrates on:
- Whether the product’s active identity matches the claim language for miconazole. [1]
- Whether the product’s formulation structure matches the claim’s vehicle/excipient constraints.
- Whether any method/use claim language is triggered by labeling and instructions for use tied to fungal skin infections. [1]
If you formulate a different azole
FTO risk generally decreases if US 3,681,357 does not claim azole compounds broadly. The claim anchor is miconazole rather than an “any azole” genus. [1]
Claim scope compared with typical follow-on topical antifungal estates
| Dimension |
US 3,681,357 direction |
Common follow-on strategy in the US |
| Active ingredient |
Anchored on miconazole identity |
Design-around by using different azoles or asserting non-literal coverage where claim language is compound-specific |
| Formulation |
Topical pharmaceutical composition with defined components/structure (vehicle constraints often matter) |
Claim avoidance via alternative vehicles, excipient systems, or delivery formats |
| Use |
Topical application to treat fungal infections |
Avoid by limiting claimed indications or changing the application regimen where feasible |
| Practical litigation posture |
Composition and use claims create product-level exposure |
Later patents can overlap on formulation variants even after early active-ingredient issues mature |
Source: US Patent 3,681,357 full text/claims. [1]
How should the patent be interpreted for competitive intelligence?
What is the main competitive takeaway
US 3,681,357 defines a topical antifungal composition centered on miconazole and its therapeutic application to fungal skin infections. Competitive products that also use miconazole must map formulation and labeling against the patent’s specific claim elements. [1]
What is the main risk-management takeaway
Competitive risk tends to concentrate on:
- miconazole-based topical formulations, not systemic or non-azole antifungals;
- specific formulation constraints if included in claim wording; and
- labeling/usage instructions if method/use claims tie treatment to the claimed fungal conditions. [1]
Key Takeaways
- US Patent 3,681,357 protects topical antifungal compositions centered on miconazole and their use for treating fungal skin infections. [1]
- Enforceable scope hinges on miconazole identity, topical formulation structure, and claimed therapeutic use language. [1]
- US competitive landscape splits into vehicle/delivery, concentration/dosing, and solid-form/process improvements, which can overlap with or work around early composition and use claims.
- For miconazole topical products, the most important diligence is a literal mapping of formulation components/structure and product labeling to the claim elements in US 3,681,357. [1]
FAQs
1) Is US 3,681,357 broad enough to cover any topical antifungal?
No. The patent is anchored on miconazole and topical antifungal treatment of fungal infections, not a general azole antifungal genus. [1]
2) Can a competitor avoid infringement by changing the vehicle (cream vs gel vs solution)?
Potentially, but infringement depends on whether independent claims require specific formulation components/structures. US 3,681,357’s claim language must be mapped to the product vehicle composition. [1]
3) Does the patent cover systemic (oral or IV) antifungal treatment?
The protection is oriented to topical antifungal use, not systemic dosing, based on the claim structure and therapeutic framing in the patent. [1]
4) Are method-of-use claims a major enforcement lever for this patent?
Yes. If claims include topical application method/use language, then product labeling and instructions for use can become relevant in infringement analysis. [1]
5) How does the patent typically interact with later azole formulation patents in the US?
Later patents often address formulation improvements and regimen tweaks. They can create overlapping estates around topical miconazole products even where earlier active-ingredient claims exist. [1]
References
[1] United States Patent. US 3,681,357. “Topical antifungal compositions” (miconazole-based). Patent claims and description.
